Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study

Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study

Background: Typhoid causes significant mortality among young children in resource-limited settings. Conjugate typhoid vaccines could significantly reduce typhoid-related child deaths, but only one WHO-prequalified typhoid conjugate vaccine exists for young children. To address this gap, we investiga...

Full description

Bibliographic Details
Main Authors: Maria Rosario Capeding, Arijit Sil, Birkneh Tilahun Tadesse, Tarun Saluja, Samuel Teshome, Edison Alberto, Deok Ryun Kim, Eun Lyeong Park, Ju Yeon Park, Jae Seung Yang, Suchada Chinaworapong, Jiwook Park, Sue-Kyoung Jo, Yun Chon, Seon-Young Yang, Ji Hwa Ryu, Inho Cheong, Kyu-Young Shim, Yoonyeong Lee, Hun Kim, Julia A. Lynch, Jerome H. Kim, Jean-Louis Excler, T. Anh Wartel, Sushant Sahastrabuddhe
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:EClinicalMedicine
Subjects:
Infants and toddlers
Typhoid
typhoid conjugate vaccine
Vi-DT
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020302844

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020302844

Similar Items